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“Nothing in life is to be feared, it is only to be understood. 
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Nos últimos anos tem aumentado a exigência para obtenção de DNA plasmídico superenrolado 
de elevada pureza de forma a ser aplicado como vector em novas estratégias terapêuticas, 
como a terapia génica ou as vacinas de DNA. Assim, é necessário implementar uma técnica 
analítica adequada para controlar a qualidade do plasmídeo superenrolado, como um produto 
farmacêutico, durante o processo de produção. O presente estudo descreve o 
desenvolvimento de uma nova metodologia para quantificar e controlar a pureza do 
plasmídeo superenrolado, usando uma coluna monolítica que se baseia em cromatografia de 
troca aniónica. Este método analítico com detecção UV permite a separação das isoformas do 
plasmídeo, usando um gradiente por passos de NaCl. Avaliou-se a selectividade, linearidade, 
exatidão, reprodutibilidade e repetibilidade do método, e também se estabeleceram os 
limites inferiores de quantificação e de detecção. A validação foi realizada de acordo com as 
directivas, sendo demonstrado que o método é preciso e exato até uma concentração de 
plasmídeo superenrolado de 200 µg/mL. O principal avanço alcançado ao usar este método é 
a possibilidade de quantificar plasmídeo superenrolado numa amostra contendo outras 
topologias do plasmídeo, num ensaio de 4 minutos. Esta coluna também possibilita a 
avaliação de plasmídeo superenrolado presente em amostras mais complexas, permitindo o 
controlo ao longo do bioprocesso. Assim, estes resultados confirmam a possibilidade de 
utilizar esta coluna monolítica associada a um método analítico poderoso no controlo do 

















The demand of high-purity supercoiled (sc) plasmid DNA (pDNA) to be applied as a vector for 
new therapeutic strategies, such as gene therapy or DNA vaccination has increased in the last 
years. Thus, it is necessary the implementation of an analytical technique suitable to control 
the quality of the sc pDNA as a pharmaceutical product, during the manufacturing process. 
The present study describes a new methodology to quantify and monitor the purity of sc 
pDNA, using a monolithic column based on anion-exchange chromatography. This analytical 
method with UV detection allows the separation of the plasmid isoforms by using a NaCl 
stepwise gradient. The selectivity, linearity, accuracy, reproducibility and repeatability of 
the method have been evaluated, and the lower quantification and detection limits were also 
established. The validation was performed according to the guidelines, being demonstrated 
that the method is precise and accurate for a sc plasmid concentration up to 200 µg/mL. The 
main advance achieved by using this monolithic method is the possibility to quantify the sc 
plasmid in a sample containing other plasmid topologies, in a 4 minutes experiment. This 
column also permits the assessment of the sc pDNA present in more complex samples, 
allowing the control of pDNA throughout the bioprocess. Thus, these findings strengthen the 
possibility of using this monolithic column associated with a powerful analytical method to 
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Chapter I - Introduction 
 
Section I - Clinical application of plasmid DNA: gene therapy or 
DNA vaccination 
In the last decades, a technological advance in medical and pharmaceutical areas allowed the 
accomplishment of several human clinical trials, testing the ability to inject plasmids 
providing therapeutic benefits for untreatable pathologies [1–4]. The rapid evolution of gene 
therapy and DNA vaccination promises to revolutionize the treatment of inherited and 
acquired diseases, by the development of specific DNA vectors in large quantities under 
pharmaceutical grade [5].  
Briefly, DNA vaccines use the plasmid DNA (pDNA) to express specific antigens on cell 
membranes, stimulating and enhancing the immune system’s response and memory [6], 
providing immunity against major killers, such as malaria [7]. On the other hand, gene 
therapy is based on the introduction of functional genes into human cells and expression of 
correct copy [8] to repair genetic defects, such as cystic fibrosis, or acquired diseases like 
cancer and AIDS [9].  
An effective application of pDNA for therapeutic benefits has been made difficult by issues 
associated with intracellular delivery, transfection efficiency and purity degree required for 
pDNA expression vectors, to avoid adverse immune responses [10]. Effective DNA vaccination 
and gene therapy require the control of both the location and function of therapeutic genes 
at specific target sites within the patient’s body [11]. Thus, one of the main challenges in the 
development of molecular medicine is to introduce naked DNA into target cells overcoming 
the extra- and intracellular barriers. 
Most gene administration methods are based on viral vectors [9,12] but this delivery system 
has raised safety and regulatory concerns because of their toxicity and immunogenicity [10]. 
Non-viral vectors, such as pDNA vectors have been considered to be safer, simpler to use and 
easier to produce on a large-scale [13,14]. Thus, the non-viral vectors overcome the problems 
associated to the viral vector-mediated therapy [11,12,15], becoming the most attractive 
gene-transfer systems to be used as biopharmaceutical products [9,11,16]. 
The clinical application of pDNA is progressing and the commercial availability for 
immunotherapeutic and gene therapy purposes is approaching reality. Plasmid DNA is 
considered a new generation biotechnology product, and several clinical trials are currently in 
progress using these vectors to treat or to prevent a wide range of diseases with complex 
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etiologies including: cancer, AIDS, allergic diseases, infectious diseases like malaria, 
neurological disorders such as Parkinson’s disease and Alzheimer’s disease, and cardiovascular 
disorders [17,18]. The consequent use of pDNA vectors in these therapeutic approaches has 
increased the need for large amounts of highly pure pDNA with a therapeutic or 
pharmaceutical-grade and the development of large-scale and efficient pDNA purification 
processes is also required [19]. 
 
 
Section II - Characteristics of pDNA biomolecule 
Plasmids are extra-chromosomal covalently closed double stranded DNA molecules found most 
frequently but not exclusively in bacterial cells [20]. They replicate independently of the cell 
chromosome, and typically carry genes that encode for antibiotic resistance [20]. On a 
molecular level, pDNA molecules can be considered pro-drugs that upon cellular 
internalization employ the DNA transcription and translation apparatus in the cell to 
biosynthesize the specific protein [17].  
Plasmid DNA molecules are very large (Mr >10
6, sizes in the µm range) when compared with 
proteins [15]. Each strand of a pDNA molecule is a linear polymer of deoxyribonucleotides 
linked by phosphodiester bonds. The phosphate groups are negatively charged for pH > 4 [21]. 
The winding of the two anti-parallel DNA strands around each other and around a common 
axis originates the classic right handed double helix structure, which is stabilized by Watson-
Crick hydrogen bonds between AT and GC base pairs and by stacking forces [21]. The inside of 
the double helix is highly hydrophobic due to the close packing of the aromatic bases [19]. 
When the helix axis of pDNA is coiled in space appears sc pDNA.  
Despite pDNA being a very stable biomolecule, during the manufacturing and recovery 
processes, it can undergo several types of stress that may disrupt its structural stability [22]. 
In this way, plasmid molecules that are mainly recovered in the sc isoform can also exist in a 
non-sc or relaxed form, such as the oc conformation resulting from the damage of the sc 
form. Other variants, such as linear (ln), denatured or oligomeric conformations can also be 
found in cell lysates [19]. If the manipulation induce nicks in one DNA strand (cleavage of the 
phosphodiester bonds), the sc pDNA uncoils to become the oc plasmid isoform; on the other 
hand, if the manipulation induce double-stranded nicks it produces the ln plasmid form [23]. 
The denatured forms exhibit a conformation where the hydrogen bonding between 
complementary strands at certain locations has been disrupted and oligomers are a 
consequence of homologous recombination [24]. 
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Supercoiled pDNA, due to its structure and conformation extremely compact and functional, 
is considered the most efficient isoform at inducing gene expression comparing with other 
conformational variants [25]. Thus, the sc pDNA isoform is the desired topological form since 
it induces the most efficient access to the nucleus of the cell and consequently improves gene 
expression in eukaryotic cells [25]. Since the diversity of pDNA forms results from the damage 
of the sc isoform, and also because this is the only naturally intact form adapted to play an 
active role in eukaryotic cell physiology [1,25,26], the attainment of the isolated and purified 
sc plasmid isoform becomes essential. 
 
 
Section III - Biotechnological process for pDNA manufacturing  
Process development for pDNA manufacturing usually starts on a bench scale, and includes 
three stages: upstream processing, fermentation and downstream processing [27] (Fig. 1). 
Generally almost all processes, for the manufacture of pDNA in sufficient quantities to clinical 
applications, need to improve the productivity [18], mainly in the following operations: 
fermentation, cell lysis, isolation and purification [28, 29]. 
 
 
Figure 1 – Schematic representation of the three stages involved in process development for pDNA 
manufacturing. (Adapted from [20, 30]) 
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In order to obtain pDNA is necessary the design of the vector to ensure safety, efficacy and 
cost-efficient production. After completing the vector construction, the transformation of a 
bacterial cell, typically Escherichia coli (E. coli), is performed with the plasmid encoding the 
gene of interest. Plasmid molecules are usually biosynthesized by autonomous replication in 
E. coli host fermentation, intending to maintain high plasmid copy number per bacterium [1]. 
After selection and optimization of growth conditions (upstream processing), the production 
is then developed by fermentation of the host cells in a bioreactor to achieve high yields of 
pDNA [31]. Finally, the isolation and purification steps (downstream processing) (Fig. 1) 
consist on the disruption of E. coli cells to recover the pDNA, which is then purified using a 
suitable methodology [19]. 
There are several techniques that can be used to disrupt E. coli cells, and hence, release 
pDNA molecules, but the most widely used method is alkaline lysis [32] or its variations [33]. 
This is the first critical step in the downstream processing of pDNA, because all the 
intracellular components, including all plasmid DNA conformations, RNA, genomic DNA 
(gDNA), endotoxins and proteins, are released [27]. Moreover, this step can affect the ratio of 
supercoiled (sc) plasmid to other forms, the plasmid amount recovered, as well as the 
physicochemical characteristics of cellular impurities that must be removed during the 
downstream process. 
The alkaline cell lysis relies on the disruption of cells at high pH with NaOH in the presence of 
SDS, followed by the release and denaturation of gDNA, cell wall material and most of the 
cellular proteins. After the lysis step, the solution is neutralized with potassium acetate, 
which precipitates SDS together with denatured gDNA and cellular debris. Different 
operations can remove this insoluble material, whereas the majority of pDNA remains in the 
supernatant. During these manipulations care should be taken to avoid shear-induced 
cleavage of gDNA, which may result in small fragments that will not aggregate. The resulting 
clarified alkaline lysate normally contains proteins, RNA, lipopolysaccharides (LPS), gDNA 
fragments and pDNA. Thus, it is generally performed the reduction of impurities content, like 
proteins and host nucleic acids, and the reduction of volume to increase the plasmid mass 
fraction by clarification and concentration operations, respectively [19,34,35] Throughout the 
process, the mechanical stress should be avoided (for example, by stirring or pumping) in 
order to minimize the risk for open circular (oc) pDNA formation [18]. 
The final step to obtain pDNA as a highly pure product for therapeutic applications is the 
recovery and purification of pDNA molecules from the clarified cell lysate, through of liquid 
chromatography, which stands as a central purification technique, both at laboratory and 
process-scale [19,28]. Several studies have been made to develop adsorbents based on 
different chromatographic principles that allow a fast and efficient separation of pDNA [19]. 
Different approaches exploit one or more of the following purification processes: size 
exclusion, anion-exchange, hydrophobic interaction and affinity chromatography [19]. Liquid 
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chromatography is crucial in process-scale manufacturing of therapeutic pDNA, since the 
quality specifications set or recommended by regulatory agencies, such as the Food and Drug 
Administration (FDA) and the European Agency for the Evaluation of Medical Products (EMEA) 
must be fulfilled [14]. The role of chromatography is then to remove those cellular host 
components (RNA, proteins, gDNA fragments, endotoxins) and non-sc pDNA variants (Fig. 1), 
in order to achieve the purification of sc pDNA [14].  Several chromatographic techniques 
have been integrated, individually or combined, into several processes for the manufacture of 
therapeutic pDNA [36]. 
The challenges in downstream processing are essentially related to eliminating host impurities 
that share common characteristics with pDNA, like negative charge (RNA, gDNA, and 
endotoxins), molecular mass (gDNA and endotoxins) and hydrophobicity (endotoxins) [18], as 
well as to isolate the sc pDNA from the other plasmid conformational variants. These facts 
render more evident the need to develop and implement efficient methods to quickly isolate 
and purify the sc plasmid isoform. Chromatographic processes can then explore some 
differences in properties, such as charge, molecular size and hydrophobicity [19]. 
Critical values for the acceptability of pharmaceutical-grade preparations are represented in 
table 1, showing all specifications that must be reliably reached in processes which are 
supposed to be used for production of therapeutic substances [18].  
 
Table 1 – Specifications of bacterial cell lysates and accepted levels of impurities for the final 
product. (Adapted from [18]) 
Content of bacterial cell lysates Final product   
Issue in focus: Range of acceptance: Determined by: 
55% Proteins proteins <3 µg/mg pDNA BCA test 
21% RNA RNA <0.2 µg/mg pDNA Analytical HPLC 
3% gDNA gDNA <2 µg/mg pDNA TaqMan-PCR 
3% LPS endotoxins <10 E.U./mg pDNA LAL test 
3% Plasmid sc over oc form >97% CGE 
15% Others    
 
Plasmid DNA represents less than 3% of the global content in the cleared lysate preparation 
(Table 1), even in the case of high copy number plasmid [18]. The removal of endotoxins is 
particularly important, since these LPS components of the E. coli cell wall can cause 
symptoms of toxic shock syndrome [37]. Furthermore, endotoxins may dramatically reduce 
transfection efficiencies in various cell lines and display cytotoxic effects on mammalian cells 
[37]. 
Finally, the plasmid product is formulated and delivered to the eukaryotic cells to express the 
protein of interest [23]. In general, all the unit operations involved in the global process are 
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adjusted in a way that pDNA can accomplish the properties to express the encoded 
information, preferably at the right place, time, and level [38].  
The global process selected has to be safe and productive as recommended by the regulatory 
agencies [19]. Considering the clinical application of pDNA, the pharmaceutical development 
of a functional, stable and sterile product for clinical trials depends heavily on the availability 
of an assay for the quantification and purity determination of active plasmid products [39]. 
Due to the particular interest in the bio-active plasmid conformation, it is crucial that this 
analytical methodology quantify only the sc isoform. Liquid chromatography is also very 
useful as an analytical tool to monitor and control pDNA quality during processing and in the 
final formulations. This type of analysis is essential to guarantee that the final product meets 
the desired specifications [19,40]. 
According to regulatory agencies, such as FDA, the product-quality is defined as a percentage 
of the sc isoform compared to the total pDNA, being that the purity of the sc pDNA must be 
100% with the homogeneity degree higher than 97% of sc isoform from E. coli host to apply in 
gene therapy and DNA vaccination [18]. Thus, it is essential that both research and industry 
improve the effectiveness of sc pDNA production and purification methodologies [28]. 
 
 
Section IV - Analytical methods for pDNA quantification 
Monitoring the performance of a pDNA manufacturing process, as well as assessing the final 
product quality considering the product specifications, are key issues in process development, 
validation and product approval [40,41]. Biopharmaceuticals based on pDNA are chemically 
highly defined and so can be analysed by chemical, biochemical and physical assays [41]. 
Assessing the quality of the final plasmid preparation in terms of its safety, potency and 
purity, in order to ensure that the product specifications are met, is a key issue for process 
validation [40,41]. The development and set-up of reliable analytical methods for the 
quantification of pDNA and assessment of its purity and homogeneity are especially 
important. 
Since methods for producing and purifying plasmids in large quantities are being developed 
[42], it is also important that quick, reliable, accurate, and inexpensive analytical methods 
can be established in order to ensure that purity levels are constantly met in each unit 





Figure 2 – The role of analytical chromatography in process-scale manufacturing of therapeutic 
pDNA. (Adapted from [19]) 
 
Although quantification of total pDNA in pure solutions is relatively easy to accomplish (for 
example, by spectrophotometry at 260 nm or fluorescence), mass estimation in impure 
process streams requires the separation of impurities such as RNA, gDNA fragments and 
proteins from plasmid molecules before quantitative detection. This separation of plasmid 
from impurities can be accomplished by electrophoresis carried out either in the conventional 
[43] or capillary operation modes [44–46]. 
Gel electrophoresis is used routinely to identify the presence of the various forms of a given 
plasmid [47], with the sc form almost always having the fastest migration rate. Gel 
electrophoresis of DNA plasmids of modest size (<50 kbp) is performed with agarose 
concentrations of 0.5–1%, while larger DNA plasmids have been separated by pulsed gel 
electrophoresis [48]. However conventional agarose gel electrophoresis is not sufficiently 
reproducible or accurate for quantitative purposes and is time consuming. Furthermore, for 
purity analysis the method is only generally accepted for a qualitative assessment of RNA 
contamination [49]. Although many researchers have quantified DNA plasmids by the imaging 




Capillary electrophoresis on the other hand combines a high degree of resolution with 
sensitivity, reproducibility and a fast analysis time. This technique is becoming more and 
more used to quantify pDNA and its topoisomers (sc and oc) [44–46]. Unfortunately, the 
superior performance of capillary electrophoresis when compared with conventional gel 
electrophoresis has a high cost associated and its routine use in research laboratories is not 
likely to occur in the near future [50]. Furthermore capillary electrophoresis does not 
adequately handle process solutions that contain significant amounts of impurities [50]. 
Although the electrochemical methods can also provide an alternative, they are also 
restricted to laboratories equipped with voltammetric and chronopotentiometric analysers 
[51]. For this reason, various chromatographic methods for determining the concentration of 
the sc pDNA and assess the purity started to emerge. The method is based on measuring the 
peak area of sc pDNA, the bio-active plasmid conformation, which is proportional to the 
concentration of this isoform. 
High-performance liquid chromatography (HPLC) is a routine technique in many research and 
industrial laboratories, which has been used for the separation and quantitation of nucleic 
acids [52]. HPLC is a fast, reproducible and robust methodology mainly based on anion-
exchange [29,49,53–55], hydrophobic interaction [20] or reversed-phase binding modes [55–
57]. Some HPLC columns can also selectively separate pDNA isoforms, thus providing a means 
to assess the heterogeneity of pDNA preparations [20,54,55]. 
Quantification of the plasmids eluting from the column is typically performed using UV 
detection at 260 nm. One recent study indicates that not only the concentration (i.e. 
amount), but also size (effective radius) and molecular mass of pDNA eluting from 
chromatography columns can be determined using light scattering [58]. 
With regard to the chromatographic methods, the hydrophobic interaction chromatography 
(HIC) allied to an HPLC system was already applied to quantify total pDNA in different 
samples [50] and to separate plasmid isoforms [20]. 
For the first time, Sousa and Queiroz (2011) have reported the assessment of the sc plasmid 
isoform using an analytical method based on arginine-affinity chromatography that allows the 
quantification and the quality control of sc plasmid biopharmaceuticals [23]. 
Anion-exchange (AEX) chromatography was also used by different authors to quantify or to 
determine the purity of plasmid samples [19,52]. In earlier experiments with anion 
exchangers, total pDNA analysis were described, using Poros HQ [59], Poros QE [29], Poros PI 
[53,60,61] and DMAE-LiChrospher [49]. An HPLC macroporous Nucleogen-DMA-4000 column 
(Macherey-Nagel) was reported to separate RNA and gDNA from pDNA, which eluted as a peak 
consisting of 95% of the sc isoform [62]. The separation and quantitation of oc and sc isoforms 
has also been achieved with DEAE-NPR and DEAE-5PW (Tosoh) columns [54]. The presence of 
nanograms of oc pDNA could be determined within 30 min [54]. One recent study documents 
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the validation of an AEX liquid chromatographic method with UV detection for the 
quantification and purity determination of the sc pDERMATT plasmid isoform (3.8 kbp). 
However, this method is time-consuming, since the total run time was 35 min [39]. Fast pDNA 
separations can be obtained by reducing the mass transfer resistance within the 
pores/channels of super-porous matrices [52]. High-performance monolithic columns [63] 
have been described as a good option to achieve this purpose. A much faster analysis of pDNA 
isoforms was obtained with a non-porous, micropellicular DEAE anion exchanger based on 
highly cross-linked PS-DVB particles [64]. 
 
 
Section V - Anion-exchange chromatography 
AEX chromatography remains one of the most used techniques for capture, purification and 
quantitation of pDNA, both at preparative and analytical scale [18,19], as it offers the 
advantages of rapid separation, no solvent requirement, possibility to be sanitized with NaOH 
and a wide selection of process-grade stationary phases [65]. 
AEX chromatography takes advantage of the interaction between negatively charged 
phosphate groups in the DNA backbone and positively charged ligands on the stationary phase 
[29]. After binding, a salt gradient is used to displace the different nucleic acids that should 
elute in order of increasing charge density, a property, which in turn is a function of chain 
length and conformation [14]. The shape and size of the molecules clearly plays an important 
role in the separation of plasmid variants [52,66]. In this way, the more compact sc forms, 
which have higher charge density, elute later than the oc forms which have lower charge 
density [62,67,68]. The stronger binding of the more compact sc pDNA can be overall 
attributed to its higher charge density in comparison with the other isoforms [62,67,68] or to 
a better fit and interaction with ligands within the stationary phase pore curvatures [62]. 
Furthermore, the base sequence and composition also may affect the elution pattern of 
nucleic acids in anion exchangers [66].  
When using AEX to separate pDNA, the clarified lysate feed should always be loaded at a 
sufficiently high salt concentration (typically >0.5 M NaCl) to avoid an unnecessary adsorption 
of low charge density impurities, such as low Mr RNA, oligonucleotides and proteins. Under 
these conditions, a significant amount of impurities elute in the flowthrough and capacity can 
be fully exploited for pDNA adsorption [62,65]. Molecules with a high charge density, such as 
pDNA isoforms, high Mr RNA and gDNA are retained and subsequently eluted by increasing the 
ionic strength of the mobile phase. Many AEX stationary phases display poor separation 
selectivity towards pDNA and impurities (high Mr RNA, pDNA concatamers, gDNA, non-sc pDNA 
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isoforms, endotoxins) due to their similar binding affinities. In the case of gDNA, separation 
will be even more difficult to accomplish if alkaline lysis generates fragments with sizes 
closer to pDNA size [15]. 
The use of pDNA chromatography has been reviewed by Diogo and co-workers (2005), being 
described that AEX, HIC and reversed phase ion-pair chromatography are the techniques 
commonly used for pDNA quantitation [19]. However AEX-HPLC is still most widely used 
[19,52]. Several groups have successfully separated the pDNA forms using AEX-HPLC 
[49,54,66,69,70].  
Several authors have reported the use of weak anion-exchange ligands such as DEAE coupled 
to silica [62] or polymer-based matrices [68], and the use of strong ligands such as quaternary 
amines (Q) coupled to polymeric matrices [67] in analytical and/or preparative 
chromatography of plasmids. However none of these groups have validated monolithic 
columns for assessment of sc pDNA isoform. 
 
 
Section VI - Monolithic columns 
A typical monolith (BIA Separations) is a continuous bed constituted by a single piece of highly 
porous material, characterized by a highly interconnected network of channels [63], with 
large diameter (0.01 – 4 µm), whose pore size depends on the polymerization process [71,72]. 
In this way, all the mobile phase is forced to flow through the channels via convection [73], 
resulting in a very fast transfer between mobile and stationary phases [74]. This 
chromatographic support named as Convective Interaction Media (CIM) was developed with 
the aim of obtaining a short chromatographic layer, ensuring well-defined, narrow pore-size 
distributions, excellent separation power and exceptional chemical stability [71]. Thus, these 
innovative CIM disks present numerous advantages comparing to conventional supports 
applied on sc pDNA purification. 
Monolithic supports exhibit very high binding capacity for pDNA [71,75] and excellent mass 
transfer properties, because present a huge quantity of accessible binding sites for large 
biomolecules as pDNA [76], due to their “superpores” which can easily accommodate large 
pDNA biomolecules. Moreover, these supports allow a fast and high-resolution separation of 
double stranded DNA molecules, making them attractive for pDNA chromatography [19]. 
In general, the plasmid purity, recovery and peak resolution are coherently influenced by 
chromatographic residence time, which consequently can be changed by manipulating buffer 
flow rate and column length [77]. In accordance, for the optimal purification of larger 
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biomolecules, the chromatographic column needs to be short, supporting higher flow rates 
[73,78] in order to reduce backpressure [63], unspecific binding, product degradation and 
minor changes in the structure of the biomolecule [79], without sacrificing resolution, due to 
short contact times with the chromatographic matrix [79]. 
The use of formats more adequate to handle large pDNA molecules, such as monoliths, will 
likely become more and more important in pDNA chromatography [19]. Monoliths are now 
being considered the material of choice for the purification and analysis of proteins, pDNA 
and viruses [76,80,81]. 
The purification of pDNA from an alkaline lysate without any addition of RNase using weak 
AEX chromatography on a CIM DEAE monolith (BIA Separations) has been described [63]. The 
pDNA quality was comparable to the quality of pDNA isolated with a commercial Qiagen kit. 
An additional advantage was the successful regeneration which allows a consecutive usage of 
the same CIM® DEAE monolithic column. The characteristic shortness of the monolith resulted 
in a fast separation (approximately 7 min) [63]. Furthermore, it was also shown that disk 
monolithic columns can be applied for fast analytical in-process control of the plasmid DNA 
purity [63]. 
Recently, it has been reported the application of monolithic innovative technology to purify 
sc pDNA suitable for pharmaceutical applications, at preparative scale, by exploiting affinity 
interactions [5,75].  Knowing that the monolithic columns have all these advantages, it will 




Section VII - Aims 
The present work aims to develop a new analytical method, efficient on sc pDNA 
quantification and purity evaluation, exploring the interaction with an anion exchange 
monolith. Since the separation and quantification of plasmid isoforms in final pDNA products 
is important, a method that can rapidly measure sc pDNA in impure solutions is very useful. 
A CIM® pDNA analytical column from BIA Separations will be explored. The monolithic support 
will be tested first with a pre-purified pDNA sample (oc + sc) to verify the separation of both 
plasmid isoforms (selectivity). 
The validation of the analytical method must be performed according to international 
guidelines [28]. Basic analytical parameters like linearity of the method, lower limits of 
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detection and quantification, accuracy and precision (intra- and inter-day) will be 
determined. In fact, the establishment of a new analytical method, able to monitor a 
biotechnological process in terms of controlling the sc pDNA quality, purity and yield, must 
guarantee the simplicity, linearity, accuracy and precision of the results.  
If the monolithic column is validated for pre-purified sample (oc + sc), it becomes interesting 
to test this support for the quantification of sc pDNA isoform directly from a clarified E. coli 
lysate. Thus, the sc pDNA amount can be determined for different samples, which are 






Chapter II - Materials and Methods 
 
Section I - Materials 
Subsection I - Chemicals 
The host strain used for obtaining the 6.05-kbp plasmid pVAX1-LacZ (Invitrogen, Carlsband, 
CA, USA) and the several nucleic acids was E. coli DH5α obtained from Invitrogen (Carlsband, 
CA, USA). Kanamycin was purchased from Sigma (St. Louis, MO, USA). QIAGEN plasmid 
purification maxi kit was from QIAGEN (Hilden, Germany). Tris(hydroximethyl)methylamine 
and isopropanol were purchased from Fisher (Leicestershire, UK). Sodium chloride and sodium 
hydroxide were obtained from Panreac (Barcelona, Spain). All solutions were freshly prepared 
using deionized water ultra-pure grade, purified with a Milli-Q system from Millipore 
(Billerica, MA, USA) and analytical grade reagents. The elution buffers were filtered through a 
0.20 µm pore size membrane (Schleicher Schuell, Dassel, Germany) and degassed 
ultrasonically. The samples to inject in monolith were filtered through 0.22 µm pore size 
filter (Millipore, Bedford, MA, USA). All salts used were of analytical grade. 
 
Subsection II - Instrumentation 
All analytical chromatography experiments were performed using ÄKTATM purifier system (GE 
Healthcare Biosciences, Uppsala, Sweden) controlled by UNICORN software, Version 5.11. This 
equipment consists of two pumps with various sample loop volumes and a UV detector. All 
DNA concentration determinations were made spectrophotometrically with Ultrospec 3000 
UV/Visible Spectrophotometer (Pharmacia Biotech, Cambridge, England). One unit of OD 260 
nm in a 10 mm cuvette is assumed to correspond to 50 µg/ml dsDNA.  
 
Subsection III - Column 
CIM® pDNA Analytical Column was kindly provided by BIA Separations (Ljubljana, Slovenia). 
CIM disk monolithic columns bearing weak anion exchanger (diethylamino) were used. CIM 
monolithic column consists of a disk-shaped poly(glycidyl methacrylate-co-ethylene 
dimethacrylate) highly porous polymer matrix with a defined morphology (pore size, and size 
distribution, porosity and shape). Their small volume (0.32 mL) and short column length (15.0 
mm length and 5.2 mm diameter) allows operation at high flow rates (up to 10 column 
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volumes/min). The disk-shaped matrix is packed into a dedicated stainless steel housing (BIA 
Separations). Regeneration of CIM disk monolithic column was performed after approximately 
50 chromatographic runs by washing it well with water followed by 10 column volumes of 0.5 
M NaOH at a flow rate of 0.2 ml/min and finally washing with water. 
 
 
Section II - Methods 
Subsection I - Plasmid and bacterial growth conditions 
The analytical method to quantify sc pDNA was developed using the 6.05-kbp plasmid pVAX1-
LacZ, chosen as model vector. The plasmid amplification was obtained by fermentation of E. 
coli DH5α after transformation, being obtained a high plasmid copy number enriched in sc 
isoform. In pre-cultivation, a stride from a selective plate of Luria-Bertani (LB) agar 
supplemented with 30 µg/mL, was inoculated into a 250 mL shake flask with 62.5 mL of 
Terrific Broth (TB) medium (20 g/L tryptone, 24 g/L yeast extract, 4 mL/L glycerol, 0.017 M 
KH2PO4, 0.072 M K2HPO4) supplemented with 30 µg/mL kanamycin. E. coli DH5α harboring 
pVAX1-LacZ was grown in a rotary shaker at 250 rpm under aerobic conditions at 37 ºC. Cell 
growth was evaluated by measuring the optical density of the culture medium at a 
wavelength of 600 nm (OD600). Pre-culture was harvested in the exponential growth phase, 
i.e., after approximately 3 h of cultivation (OD600~2.6). Fresh TB medium was inoculated with 
the appropriate amount of pre-culture, in order to start all the cultures with an OD600 of 
approximately 0.2. Growth was carried out in 1 L shake flasks containing 250 mL of TB 
medium, under the same conditions for 14 h (overnight), i.e.,  the cell growth was suspended 
at late log phase (OD600~9). The culture medium was transferred to centrifuge bottles and the 
cells were recovered by centrifugation at 5445 x g for 30 min at 4 ºC. The supernatants were 
discarded and the bacterial pellets were stored at -20 ºC. E. coli DH5α cells without plasmid 
were also grown under the same conditions as described before, but with no antibiotic 
present. 
 
Subsection II - Alkaline cell lysis and pre-purification of pVAX1-LacZ 
In order to obtain plasmid samples for initial experiments, pDNA was purified using the 
Qiagen (Hilden, Germany) plasmid maxi kit, according to the manufacturer’s instructions. The 
protocol is based on a modified alkaline lysis procedure, being considered a critical unit 
operation, because this step can influence the final ratio of sc plasmid. Unfavorable 
environmental conditions, such as extreme pH and temperature, affect the helical repeat of 
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DNA promoting its unwinding, being generated other forms such as oc isoform. Bacterial 
pellets were thawed and resuspended in 20 mL of 50 mM Tris–HCl, 10 mM EDTA, pH 8.0 with 
100 µg/mL RNase. Alkaline lysis was performed by adding very carefully 20 mL of a 200 mM 
NaOH, 1% (w/v) SDS solution. After 5 min of incubation at room temperature, cellular debris, 
gDNA and proteins were precipitated by gently adding 20 mL of prechilled 3 M potassium 
acetate solution, pH 5.5 followed by incubation on ice for 20 min. The precipitate was 
removed by centrifugation at 20 000 × g for 30 min at 4 ºC, using a Sigma 3–18 K centrifuge. A 
second centrifugation step was carried out for 15 min under the same conditions to separate 
the remaining suspended material. Following lysis, binding of pDNA to the Qiagen anion 
exchange resin is promoted under appropriate low-salt and pH conditions (750 mM NaCl, 50 
mM MOPS, 15% isopropanol (v/v), 0.15% Triton® X-100 (v/v), pH 7.0). Impurities are removed 
by a medium-salt wash (1.0 M NaCl, 50 mM MOPS, 15% isopropanol (v/v), pH 7.0), and pDNA is 
eluted in a high-salt buffer (1.25 M NaCl, 50 mM Tris-HCl, 15% isopropanol (v/v), pH 8.5). 
Plasmid DNA is then concentrated through an isopropanol precipitation, by adding 0.7 
volumes of ice-cold isopropanol, followed by centrifugation at 15 000 x g for 30 min at 4 ºC, 
using a Sigma 3–18 K centrifuge. Pellet was air-dried for 5-10 min at room temperature and 
redissolved in a suitable volume of buffer with adjusted ionic strength (approximately 3 mL of 
10 mM Tris-HCl, 700 mM NaCl, pH 8.0). Finally, 260 and 280 nm absorbance of the samples 
was determined using spectrophotometer to assess pDNA quantity and purity. In general, the 
pDNA obtained at the end of these recovery and isolation steps contained around 90% of sc 
isoform, while the remaining 10% corresponded to the presence of oc isoform, as revealed by 
agarose electrophoresis. The pDNA samples were stored at -80 ºC until analytical 
chromatographic studies. 
 
Subsection III – Isolation of plasmid DNA isoforms 
1. Supercoiled isoform 
In order to improve the quantity of sc isoform obtained in the plasmid sample, the 
fermentation was suspended at exponential phase (OD600~5), reducing the culture time to 5 h. 
The sc isoform was purified after alkaline lysis using the Qiagen (Hilden, Germany) plasmid 
maxi kit, according to the manufacturer’s instructions described above. 
2. Open circular isoform 
Open circular pDNA isoform was prepared by incubating a sc pDNA sample without NaCl at 
room temperature (20 - 25 ºC). The sample was monitored over the time by electrophoresis 
analysis until the total conversion of sc plasmid to oc isoform was observed (about 3 days). 
Samples were stored at -80 ºC until analysis. For the chromatographic analysis the ionic 
strength of the oc pDNA sample was adjusted, dissolving the required NaCl quantity to obtain 
a final concentration of 700 mM. 
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3. Linear isoform 
The linear pVAX1-LacZ sample was prepared by enzymatic digestion with Hind III (Takara Bio, 
Shiga, Japan), a single-cutting restriction enzyme. The plasmid samples, without NaCl, were 
incubated at 37 ºC for 1 h, according to the protocol of the manufacturer. Successful 
linearization of the plasmid was confirmed by agarose gel electrophoresis, being obtained 
only one band at 6050 bp. Linear plasmid was stored at -80 ºC until analysis. For the 
chromatographic analysis the ionic strength of the ln pDNA sample was adjusted, dissolving 
the required NaCl quantity to obtain a final concentration of 700 mM. 
 
Subsection IV – Isolation of host nucleic acids 
Host nucleic acids (gDNA and RNA) were isolated from pDNA-free DH5α E. coli cells.  
1. gDNA 
Genomic DNA was isolated using the Wizard genomic DNA purification kit from Promega 
(Madison, WI, USA), according to the manufacturer’s instructions. Briefly, bacterial pellets 
(65 mL) were resuspended in 25 mL of nuclei lysis solution and incubated at 80 ºC for 5 min to 
lyse the cells. After cooling the solution to room temperature, 250 µL of 1 mg/mL RNase 
solution were added to the cell lysate, followed by incubation at 37 ºC for 45 min. Then, 5 mL 
of protein precipitation solution were added to the RNase-treated cell lysate. The pellet was 
removed by centrifugation at 16 000 x g for 10 min. After centrifugation, 12.5 mL of room 
temperature isopropanol were added to the supernatant and the solution was mixed by 
inversion until the thread-like strands of DNA form a visible mass. The solution was 
centrifuged at 16 000 x g for 6 min and the supernatant discarded. The pellet was air-dried 
for 5-10 min and 12.5 mL of 70% ethanol were added to wash the DNA pellet. The solution 
was centrifuged at 16 000 x g for 6 min and, after discarded the supernatant, the pellet was 
air-dried for 5-10 min. Finally, 2.5 mL of DNA rehydration solution were added, followed by 
incubation at 65 ºC for 1 h. The gDNA samples were stored at -20 ºC until used in 
chromatographic studies. 
2. RNA 
For RNA isolation, the cells were lysed by a modification of the alkaline method [43]. Thus, 
after cell lysis, clarification was performed by adding 1 volume of 5 M solution of a chaotropic 
salt (ammonium acetate). After 30 min-incubation at room temperature the mixture was 
centrifuged at 21 000 x g for 40 min at 4 ºC. Pellets were discarded and nucleic acids 
precipitated and concentrated by adding 1 volume of a solution of 15% poly(ethylene glycol) 
(PEG) 6000, 1.6 M NaCl. After 30 min on ice and centrifugation at 21 000 x g for 40 min, 




Subsection V - Preparation of process samples  
The evaluation of the applicability of the analytical method to quantify the sc pDNA isoform 
present in more complex samples required the preparation of E. coli lysates. Thus, E. coli 
cells were lysed using a modification of the alkaline method [43], as described by Diogo and 
co-workers (2000) [82]. Bacterial pellets (obtained from centrifugation of 250 mL cell broth at 
5445 × g for 30 min, 4 ºC) were thawed and resuspended in 20 mL of 50 mM glucose, 25 mM 
Tris–HCl, 10 mM EDTA, pH 8.0. Alkaline lysis was performed by gently adding 20 mL of a 200 
mM NaOH, 1% (w/v) SDS solution. After 5 min of incubation at room temperature, cellular 
debris, gDNA and proteins were precipitated with 16 mL of prechilled 3 M potassium acetate, 
pH 5.0 and incubating on ice for 20 min. The precipitate was removed by centrifuging twice 
at 20 000 × g for 30 min at 4 ºC with a Sigma 3–18 K centrifuge. Samples of this supernatant 
were then kept and stored at -80 ºC for further analysis. The concentration of the lysate was 
performed according to a previously published method [82]. The pDNA present in the 
supernatant was precipitated by adding 0.7 volumes of ice-cold isopropanol and incubating on 
ice for 30 min. The pDNA was recovered by centrifugation at 16 000 × g for 30 min at 4 ºC. 
After discarding the supernatant, the pellet was air-dried for 5–10 min and then redissolved in 
6 mL of 10 mM Tris–HCl buffer, pH 8.0. Samples of this concentrated lysate were then kept 
and stored at -80 ºC for further analysis. The same procedure was used to perform the lysis of 
a pDNA-free cell culture. Samples were adequately diluted prior to analysis. 
 
Subsection VI - Analytical chromatography 
All experiments were performed using an ÄKTA Purifier system (GE Healthcare Biosciences, 
Uppsala, Sweden) with the Unicorn control system Version 5.11. Briefly, the system was 
prepared with a 500 mM NaCl in 10 mM Tris-HCl buffer pH 8.0 in the pump A (mobile phase 
A), and 1 M NaCl in 10 mM Tris–HCl  buffer pH 8.0 in the pump B (mobile phase B). The 
monolithic column was equilibrated with 52% of buffer B. Afterward, 20 µL of a plasmid 
sample suitably diluted in the equilibration buffer with the adjusted ionic strength were 
injected in the monolith and eluted at a flow rate of 1 mL/min. After elution of unbound 
species, the ionic strength of the buffer was instantaneously changed to 100% of buffer B to 
elute bound species. Fractions were pooled according to the chromatograms obtained and 
used for further electrophoresis analysis after concentration and desalting with Vivaspin 
concentrators (Vivascience). Next, the column was re-equilibrated for 9 min with the 
equilibration buffer in order to prepare the column for the next run. In all separations and 
throughout the entire chromatographic run the absorbance of the eluate was monitored at 
260 nm and the conductivity was continuously recorded, while 250 µL fractions were pooled 
according to the chromatograms obtained. All experiments were performed at room 
temperature (about 20 – 25 ºC). The experiments developed with the E. coli lysate or with the 
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isolated impurities, namely, oc and ln pDNA isoforms and host nucleic acids (gDNA and RNA), 
were performed using the same elution gradient described above.  
 
Subsection VII - Agarose gel electrophoresis 
The identification of the nucleic acids samples was performed by agarose gel electrophoresis. 
Briefly, the fractions recovered from each chromatographic experiment, after being 
efficiently desalinized, were analyzed by horizontal electrophoresis using 15 cm 1% agarose 
gels (Hoefer, San Francisco, CA, USA) stained with green safe (1 µg/mL) and visualized under 
UV light in a Vilber Lourmat system (ILC Lda, Lisbon, Portugal). Electrophoresis was carried 
out in Tris-acetic acid (TAE) buffer (40 mM Tris base, 20 mM acetic acid and 1 mM EDTA, pH 
8.0) and run at 100 V for 40 min. Finally, the bands corresponding to nucleic acids were 






Chapter III – Results and Discussion 
 
Section I – Establishment and validation of the analytical 
procedure for assessment of purity and quantification of 
supercoiled plasmid 
According to the FDA guidelines, the quantification of pDNA and the analysis of its purity must 
be evaluated using suitable analytical methods [1], and the high performance 
chromatographic techniques are usually applied to ensure the plasmid quality considering the 
clinical application. The correct validation of an analytical procedure involves the control of 
several parameters. Thus, in this study, the specificity, the linearity, the accuracy, the 
reproducibility, the repeatability, and the lower quantification and detection limits were 
evaluated. 
 
Subsection I - Specificity 
The specificity of an analytical method is described as the ability to assess unequivocally the 
analyte in the presence of components which may be expected to be present [83], which in 
this case can be considered as the ability of the method to distinguish between both plasmid 
isoforms. To achieve the specificity of the method to assess sc pDNA it was necessary to 
define an appropriate strategy for the optimization of chromatographic conditions allowing 
the separation of pDNA isoforms. In this way, the two main plasmid isoforms, oc and sc, were 
first isolated by QIAGEN plasmid maxi kit. With this plasmid sample, some initial screenings 
were performed in order to achieve optimal resolution between sc and oc pDNA isoforms. 
These experiments were carried out in order to achieve the most appropriate binding/elution 
conditions to separate the isoforms within a short time. Thus, linear and stepwise gradients 
were tested. 
Initially, the linear gradient was evaluated by using a buffer A consisting in a Tris–HCl buffer 
at pH 8.0 and a buffer B containing 1 M NaCl in Tris–HCl buffer. Linear gradient, represented 
by the dashed line in Figure 3, was carried out in the range between 0 and 100% of buffer B, 
for 20 min (Figure 3a). After the equilibration of the column, the pDNA sample containing the 
oc and sc plasmid isoforms was applied to the analytic column. Figure 3a presents the 
chromatographic profile where it is observed only one peak with a retention time of 16.45 
min. Since a unique peak was obtained, it was concluded that there was no separation of 
isoforms, and all pDNA was eluted at the same time, under these chromatographic conditions. 
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This result indicated that all biomolecules were retained at low NaCl concentrations and were 
eluted by increasing the ionic strength. 
The next step was to evaluate the result of shortening the concentration range used in the 
linear gradient, to obtain a mild gradient. In order to choose the concentration range to be 
used in this second linear gradient strategy, it was considered that in the first assay the 16.45 
min-peak corresponded to the elution of pDNA at about 84% of buffer B. Thus, the new 
gradient was initiated with 70% of buffer B (Figure 3b). In this way, the reduction of the 
gradient range (70-100%B) also allowed to decrease the length of the gradient to 15 min. 
Under these conditions, it was also obtained only a single peak and it was not possible to 
isolate sc isoform. 
 
 
Figure 3 – Chromatographic analysis of native pDNA (oc+sc) using the monolithic column based on 
anion-exchange chromatography. (a) Chromatographic profile using a 20-min linear gradient in the 
range 0-100%B. (b) Chromatographic profile using a 15-min linear gradient in the range 70-100%B. 
 
Thereby it was concluded that the NaCl linear gradients tested, led to the total pDNA elution 
with no separation of plasmid isoforms. So, further experiments were developed in order to 
find the exact NaCl concentration that allows the elution of each isoform, and a stepwise 
gradient was explored to facilitate the separation of sc and oc pDNA.  
A stepwise gradient was tested and after some adjustments in the concentration of salt to be 
used for pDNA separation, it was possible to obtain two resolved peaks. The next step was to 
adjust the composition of the buffers and of the sample, to facilitate the complete separation 
of both isoforms. The NaCl concentration of buffer A was changed to 500 mM in the same 
Tris–HCl buffer and the concentration of buffer B was maintained at 1M of NaCl. As there was 
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an abrupt change in conductivity when injecting the sample, the ionic strength of the sample 
was adjusted to 700 mM NaCl. Although it could be possible to optimize the linear gradient 
strategy, the stepwise gradient was finally chosen because it enabled faster separations. In 
this case, after establishing the concentration of salt that allowed the separation of isoforms, 
it was possible to develop a rapid assay (Figure 4a). Figure 4b presents an agarose 
electrophoresis where it is observed in lane 1 the pDNA sample containing the oc and sc 
plasmid isoforms. This sample was applied to the analytic column and two peaks were 
obtained when using the stepwise gradient represented by the dashed line (Figure 4a). The 
elution of the first plasmid component was verified at 0.38 min using a gradient condition 
corresponding to 52% of buffer B. After 2 min of the chromatographic run, a stepwise gradient 
was created, by adjusting the elution conditions to 100% of buffer B, and the elution of the 
second component was observed with a retention time of 2.89 min (Figure 4a). 
 
 
Figure 4 – Analysis of pDNA using the analytical method based on anion-exchange chromatography. 
(a) Chromatographic profile of a pDNA sample containing the open circular and supercoiled isoforms. (b) 
Agarose gel electrophoresis analysis of each peak obtained in respective chromatogram. Lane M – 
molecular weight marker; lane 1 – pDNA sample (oc + sc) injected onto the monolithic column; lane 2 – 
oc pDNA recovered from the first peak of the chromatogram; lane 3 – sc pDNA recovered from the 
second peak of the chromatogram. 
 
Figure 4b presents the isolated isoforms, the oc conformation in lane 2 and the sc 
conformation in lane 3, which were recovered from analytic column in the first and second 
peaks, respectively. In this way, these results show that an analytical method can be 
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developed using the AEX monolithic column to specifically analyze sc pDNA. Briefly, a NaCl 
concentration of approximately 760 mM (52%B) can be used to recover the oc isoform and by 
increasing the ionic strength to 1 M the bound sc isoform is recovered.  
The total run time of the analytical experiment was of 4 min, which represents an advantage 
because the separation of pDNA isoforms and the elution of sc pDNA occurs faster than the 
described for other methods, for example in an AEX-based method that requires 35 min to 
complete the run [39] and an analytical method based on arginine-affinity chromatography 
that requires 12 min to complete the run [23]. Moreover, comparing this column with another 
monolithic column described by Branovic and co-workers (2004), both have the same run 
time, however this method offers the possibility to isolate only the sc isoform [63]. 
To confirm the identification of the plasmid components eluting in both differentiated peaks, 
two experiments were also performed by injecting each isolated plasmid isoform into the 
analytic column, under the same gradient conditions (Figure 5). Thus, the isolated isoforms, 
oc and sc pDNA conformations were used to compare their retention patterns with the elution 
profiles and retention times obtained with the sample of total plasmid (oc + sc) represented 
in Figure 4a. 
 
 
Figure 5 - Analysis of isolated pDNA isoforms using the analytical method based on anion-exchange 
chromatography. (a) Chromatographic profile of open circular pDNA isoform. (b) Chromatographic 
profile of supercoiled pDNA isoform. 
 
In Figure 5a it is possible to observe the chromatographic profile obtained by the injection of 
the oc plasmid conformation. As it is visible, one peak was obtained with a retention time of 
0.53 min, being coincident with the elution of the first peak in Figure 4a. Furthermore, the 
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application of the isolated sc plasmid isoform (Figure 5b) onto the monolithic column resulted 
in the elution of a single peak with a retention time of 2.92 min, corresponding to the second 
peak obtained in the chromatographic analysis of total pDNA. Thus, with these experiments it 
was possible to verify the specificity of the analytical method to efficiently distinguish 
between both major plasmid conformations.  
Once the predominant attractive forces involved in AEX chromatography are electrostatic 
forces between positively charged ligands on the stationary phase and negatively charged 
phosphate groups in the pDNA backbone [52], the more compact sc isoform, which has a 
higher charge density, elute later than the oc isoform. This fact was verified with the elution 
strategy used, because the first step allowed the immediate elution of the non-retained oc 
isoform and the second step, with higher ionic strength, was suitable for the total recovery of 
the sc isoform. In fact, the stronger binding of the more compact sc pDNA to diethylamino 
ligands (weak anion exchangers) can be due to its higher overall charge density, in 
comparison to other isoforms, or to a better fit and interaction with ligands within the 
stationary phase pore curvatures. 
In this context, the specificity found for sc pDNA is extremely relevant as it is required for the 
implementation of a new analytical technology able to ensure the quality and purity criteria 
of a bioproduct, like pDNA. However, other parameters have to be established to validate an 
analytical method. 
 
Subsection II - Linearity 
The linearity of this method was studied for two different concentration ranges. The first 
curve was performed with 5 sc pDNA standards in the range of 2 – 20 µg/mL (2, 5, 10, 15 and 
20 µg/mL) using three replicates for each sc plasmid concentration. The second curve was 
performed with 6 sc pDNA standards in the range of 20 – 200 µg/mL (20, 50, 75, 100, 150 and 
200 µg/mL) using four replicates for each sc plasmid concentration. The standards were 
prepared with the sc pDNA obtained from fermentation suspended at exponential phase 
(OD600~5) and purified with a Qiagen commercial kit. Considering that 1 unit of absorbance 
corresponds to a concentration of 50 µg/mL, the initial absorbance of the sc plasmid sample 
was measured in UV at 260nm. Each standard was obtained by dilution of the sc plasmid 
solution with the mobile phase used in the beginning of the chromatographic experiment. The 
pDNA standard samples were then injected into the analytic column using the procedure 
described above. The average plasmid peak area was determined and the standard deviation 





Figure 6 - Calibration curves obtained from the correlation between the supercoiled pDNA peak 





Figure 7 - Chromatographic profiles obtained for three supercoiled pDNA standards in each 
calibration curve, with the concentration of (a) 2, 10 and 20 µg/mL; and (b) 20, 100, 200 µg/mL. 
 
With this study it was verified that the method is linear within the concentration ranges 
studied (2 – 20 and 20 - 200 µg/mL). A linear correlation was found for the sc pDNA 
concentration range considering either the height or area of the sc pDNA peak. In fact, the 
correlation coefficients for the first curve were of about 0.9984 and 0.9997, respectively and 
for the second curve were of about 0.9986 and 0.9994, respectively. The correlation found for 
the calibration curves relating the sc pDNA concentration range with the peak area is 
presented in Figure 6. In Figure 7 it is possible to observe an example of the chromatographic 
profiles obtained for three sc pDNA standards of each curve, where it is verified the elution of 
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the sc pDNA at 2.9 min in all experiments. The standard deviation was found to be lower than 
0.22 µg/mL for all standards analyzed in the first curve and lower than 1.3 µg/mL in the 
second curve, providing a good indication of the method reproducibility. 
In this study the linearity was found for the concentration range of 2 - 200 µg/mL. A similar 
range (2 - 150 µg/mL) was already established in AEX [39] and affinity methods [23]. Other 
authors have also described alternative methods based on hydrophobic interaction 
chromatography (HIC) [20,50] and AEX chromatography [82] that were not efficient on 
plasmid isoforms separation and assessment, and the linearity was only studied for a 
concentration range between 2.5 and 20 µg/mL [50]. Hence, this new method presents a 
great advantage over the hydrophobic-based methods because of the possibility to quantify 
specifically the sc plasmid isoform. The assessment of this conformation is a major concern 
for the industry focused on the production and purification of pDNA, since a higher than 97% 
of sc pDNA homogeneity is mandatory for this bioproduct to be applied in gene therapy and 
DNA vaccination [18]. For this reason, this methodology proved to be simple, selective and 
linear in a concentration range adequate to measure sc pDNA content and to assess its purity 
as a pharmacological product [39]. 
 
Subsection III - Accuracy, limit of detection and limit of quantification 
In relation to the accuracy of the method, it was assessed by back-calculated concentration 
for all the standards and for an intermediate sc pDNA concentration of each curve (7.5 or 80 
µg/mL depending on the curve). Thus, a comparison was made between the nominal 
concentration of the samples and the sc pDNA concentration obtained from the calibration 
curve. Furthermore, the coefficient of variation and the mean relative error [(measured 
concentration−nominal concentration)/nominal concentration×100] were determined to 
conclude about the accuracy of this method (Tables 2 and 3).  
 





concentration ± SD 
(µg/mL) 
CV (%) Mean relative error 
(%) 
2 1.93 ± 0.12 6.23 -3.27 
5 4.95 ± 0.13 2.69 -1.07 
7.5 7.45 ± 0.20 2.74 -0.61 
10 9.84 ± 0.14 1.41 -1.63 
15 14.76 ± 0.22 1.46 -1.57 









concentration ± SD 
(µg/mL) 
CV (%) Mean relative error 
(%) 
20 17.43 ± 0.26 1.50 -12.84 
50 49.71 ± 0.84 1.69 -0.58 
75 75.67 ± 0.43 0.57 0.89 
80 80.24 ± 0.89 1.10 0.29 
100 102.48 ± 1.37 1.33 2.48 
150 153.27 ± 1.75 1.14 2.18 
200 201.60 ± 1.58 0.79 0.80 
 
 
In the first calibration curve (2 - 20 µg/mL) the lower value (2 µg/mL) shows the highest 
coefficient of variation (about 6 %) and the highest mean relative error (about -3%) (Table 2). 
In the second calibration curve (20 - 200 µg/mL) the highest coefficient of variation (about 2 
%) also corresponds to the lower standards (20 and 50 µg/mL) and the highest mean relative 
error (about -13%) belongs to concentration of 20 µg/mL (Table 3). With regard to these 
results, it was possible to conclude that the accuracy is adequate for all the standards of the 
calibration curves and for a pDNA intermediate concentration of each curve (7.5 and 80 
µg/mL), because both parameters (the coefficient of variation and the mean relative error) 
were within the range of ±15% of the nominal concentration, accepted by the guidelines [84]. 
The lower limit of quantification (LLOQ) was defined as the lowest concentration of sc pDNA 
that could be assessed with suitable precision (a coefficient of variation lower than 20%) and 
adequate accuracy, i.e. within ±20% of the nominal concentration [84]. The limit was 
established as 2 µg/mL, which shows a coefficient of variation of 6% that is below the value of 
20% accepted by the guidelines [83]. Although some works describe LLOQ of 1 µg/mL for total 
pDNA using weak anion exchange [82] the limit found for this new analytical technique is in 
accordance with the limit described by other authors who have developed AEX [39] and 
analytical affinity methods [23]. On the other hand, higher values can be found, for example 
for HIC [50] which describes LLOQ of 2.5 µg/mL in quantification of total pDNA. 
The limit of detection (LOD) of the method was determined to be 1 µg/ ml. In fact, the study 
of lower sc pDNA concentrations revealed an increased signal-to-noise that restricts the 
precise and accurate detection of the sc isoform peak. The determination of the signal-to-
noise ratio is performed by comparing measured signals from samples with known low 
concentrations of pDNA with those of blank samples and establishing the minimum 
concentration at which the analyte can be reliably detected [83]. A signal-to-noise ratio 
between 3 or 2:1 is generally considered acceptable for estimating the detection limit [83], 
justifying the establishment of the value of 1 µg/ml for the LOD, because the height of the 
blank was 3.82 mAU and height of the standard of 1 µg/ml was 8.60 mAU (Figure 8). Some 
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works also describe limits of detection of 1 µg/mL [50]. On the other hand, an AEX method 
[39] and an analytical affinity technique [23] describe LOD of 2 µg/ ml. 
 
 
Figure 8 - Chromatographic profile obtained for blank and for sc plasmid standard with the 
concentration of 1 µg/mL. 
 
The blank was performed by injecting a 700 mM NaCl solution in 10 mM Tris-HCl pH 8.0. The 
chromatographic profile of the blank shows a small peak at 2.86 min. This system peak results 
from the changes on the sodium chloride concentration in the eluent (Figure 8). This figure 
also shows the chromatographic profile of the standard of 1 µg/ ml. By comparing the height 
of both chromatograms (Figure 8, red and green lines) is possible to see that the standard of 1 
µg/ ml has more than twice the height of the blank. 
 
Subsection IV - Precision 
According to the guidelines, the precision of an analytical procedure expresses the closeness 
of agreement between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the analytical conditions [83,84]. In the validation protocols, 
precision may be considered at two levels, the repeatability and the reproducibility, that are 
usually expressed as the variance, standard deviation, mean relative error or coefficient of 
variation of a series of measurements. 
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In this work, the precision of the method was evaluated on the basis of repeatability and 
reproducibility, also termed as intra-day and inter-day precision, respectively. The intra-day 
repeatability of the method was assessed by performing four consecutive injections of three 
sc pDNA samples at three different levels of concentration (low, medium and high) under 
selected conditions. The same samples were also analyzed over a period of four consecutive 
days to determine the inter-day precision. The data presented in Tables 4 and 5 show the 
coefficient of variation and mean relative error for the three sc pDNA concentrations of each 
curve (2, 7.5 and 20; and 20, 80 and 150 µg/mL, respectively). 
 
Table 4 - Intra-day and inter-day precision for the assessment of sc pDNA in the range of 2 – 20 
µg/mL (n=4). 






± SD (µg/mL) 








± SD (µg/mL) 
CV (%) Mean 
relative 
error (%) 
2 1.93 ± 0.12 6.23 -3.27  2 2.08 ± 0.17 8.12 3.75 
7.5 7.45 ± 0.20 2.74 -0.61  7.5 7.18 ± 0.21 2.92 -4.29 
20 19.69 ± 0.30 1.52 -1.53  20 19.28 ± 0.33 1.73 -3.61 
 
 
Table 5 - Intra-day and inter-day precision for the assessment of sc pDNA in the range of 20 – 200 
µg/mL (n=4). 






± SD (µg/mL) 








± SD (µg/mL) 
CV (%) Mean 
relative 
error (%) 
20 18.77 ± 0.35 1.87 -6.14  20 18.48 ± 1.43 7.72 -7.61 
80 83.13 ± 2.48 2.99 3.91  80 83.77 ± 3.94 4.71 4.71 
150 153.47 ± 4.22 2.75 2.31  150 155.74 ± 7.82 5.02 3.83 
 
 
Table 4 shows the values of intra-day and inter-day precision for the first curve. The 
coefficients of variation for the intra-day precision were lower than 6.23% and for the inter-
day precision a maximum value of 8.12% was obtained. The mean relative error for the intra-
day experiments was between – 3.27 and – 0.61%, and the inter-day values did not deviate 
more than 4.29% from the nominal concentration (Table 4). In the second curve the 
coefficients of variation of intra-day precision were not higher than 3% and for the inter-day 
precision a value close to 8% was achieved. The mean relative error for the intra-day 
experiments was between – 6.14 and 3.91%, and the inter-day values deviated up to -7.61% 
from the nominal concentration (Table 5). With these results, it was possible to conclude that 
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Section II – Assessment of sc pDNA in process solutions 
After the validation of the method to isolate and quantify sc pDNA present in samples 
containing sc and oc pDNA, it was also explored the possibility of applying this analytical 
method for assessment of complex samples recovered from different bioprocess steps. First, 
the elution profile of each impurity was investigated by injecting isolated oc pDNA, ln pDNA, 
RNA or gDNA, onto the column. After this, some complex samples recovered from different 
bioprocess steps were also analyzed and finally, the analytical method was validated for 
impure plasmid solutions. 
 
Subsection I - Open circular pDNA isoform 
In the previous section it was proved that it is possible to separate the oc isoform from the sc 
(Figure 4). It was also shown that by injecting only oc isoform that is not retained, the elution 
occurred immediately after injection (Figure 5a), in contrast to the sc isoform which is 
retained (Figure 5b).  In the chromatogram of Figure 5a is possible to verify that the elution 
profile of the oc isoform results in two non-resolved peaks, with a slight difference from the 
chromatographic profile presented in Figure 4a. This is probably caused by the appearance of 
some ln pDNA in the oc pDNA sample. In fact, the room temperature incubation, previously 
described to induce the conversion of the sc pDNA into oc isoform [75] can also induce the 
formation of ln pDNA. Another similar technique has been described by Levy and co-workers 
(2000), in which the solutions were incubated at 60 ºC for 48h, to accelerate chemical 
degradation of the sc isoform to oc and ln isoforms [51]. However there are more appropriate 
methods, but more expensive to prepare this isoform [39, 20]. Briefly, the oc isoform could 
be prepared by incubating sc pDNA with the nicking enzyme, which cuts only one strand of 
double stranded DNA. In this way, it would be controlled the formation of other isoforms that 






Subsection II - Linear pDNA isoform 
To verify the elution pattern of the linear form of the plasmid in the chromatogram, this 
isoform was also injected in the column. The analytical chromatogram presented in Figure 9a 
shows the first peak of non-retained species at 0.32 min. 
 
 
Figure 9 – Analysis of linear pDNA isoform using the analytical method based on anion-exchange 
chromatography. (a) Chromatographic profile of ln pDNA sample. (b) Agarose gel electrophoresis 
analysis of each peak obtained in the chromatogram. Lane M – molecular weight marker; lane 1 – ln 
pDNA sample injected onto the monolithic column; lane 2 – 0.32 min-peak; lane 3 – 2.68 min-peak. 
 
The analytical chromatogram of Figure 9a shows the first peak of non-retained species at 0.32 
min. This peak corresponds to ln isoform, as confirmed by agarose gel electrophoresis (Figure 
9b), which shows in lane 2 the presence of one band with the size of approximately 6000 bp, 
corresponding to the size of the plasmid that has 6050 bp. In addition, the migration of this 
band coincides with the band of the ln pDNA sample injected into the column, represented in 
lane 1. Nevertheless, the lane 2 also shows a slight band above the previous one, which may 
correspond to some oc isoform present in the sample. In the 2.68 min-peak there is still 
present trace amounts of ln pDNA, probably because of the high ln pDNA concentration. In 
fact, the concentration of ln pDNA in samples to be analyzed is commonly low, so it is 




Subsection III - RNA 
The chromatographic profile of RNA, under the same elution conditions, shows a single peak 
eluting at 0.34 min (Figure 10a). This peak was recovered and analyzed by agarose gel 




Figure 10 – Analysis of RNA using the analytical method based on anion-exchange chromatography. 
(a) Chromatographic profile of the RNA sample. (b) Agarose gel electrophoresis analysis of each peak 
obtained in the chromatogram. Lane M – molecular weight marker; lane 1 – RNA sample injected onto 
the monolithic column; lane 2 – 0.34 min-peak. 
 
Furthermore, this result indicates the possibility of using this column to assess sc pDNA in 
samples prepared without any RNase addition. Actually, even using samples with high RNA 
concentration it was not verified any interference with the elution of sc pDNA. 
 
Subsection IV - Genomic DNA 
The chromatographic profile of the gDNA shows a main peak at 0.39 min (Figure 11a). This 
peak was recovered and injected on lane 2 of agarose gel electrophoresis (Figure 11b), but it 




Figure 11 – Analysis of genomic DNA using the analytical method based on anion-exchange 
chromatography. (a) Chromatographic profile of a gDNA sample. (b) Agarose gel electrophoresis 
analysis of each peak obtained in the chromatogram. Lane M – molecular weight marker; lane 1 – gDNA 
sample injected onto the monolithic column; lane 2 – first chromatographic peak; lane 3 – second 
chromatographic peak. 
 
Regarding the analysis of gDNA, it should be considered that during the manipulations of 
gDNA, care should be taken to avoid shear-induced cleavage of this molecule, which may 
generate small gDNA fragments with sizes closer to pDNA size. In this case, separation and 
detection could be even more difficult to accomplish. The preparation of the gDNA samples 
requires the use of alkaline lysis which can induce the product degradation. The fact that the 
species eluting in the first peak are not visible in the electrophoresis may be attributed to 
this degradation. However, to confirm this it could be used a PCR technique. In this way it 
would be quantified the gDNA present in the collected fraction corresponding to this large 
peak, confirming the elution of non-retained biomolecule. 
In the second peak there is still present trace amounts of gDNA, as confirmed by agarose gel 
electrophoresis (Figure 11b), because the lane 3 shows one faint band that coincides with the 
band present in lane 1. However, if it is injected a sample with lower gDNA concentration this 






Subsection V - Clarified lysate  
Since all isolated impurities eluted in the first gradient step defined for the separation of 
plasmid isoforms, and it was not verified a significant interference with the elution of sc 
pDNA, it was possible to test the application of the method to analyze a complex sample, 
such as an E. coli lysate, in the same elution conditions. Thus, it was first confirmed if the 
complex sample would present the same retention and elution behaviour that each isolated 
impurity. 
Briefly, lysate samples of E. coli cells transformed and non-transformed with pDNA were 
recovered before and after isopropanol precipitation. So, samples collected throughout this 
clarification process were analyzed by the analytical method (Figures 12, 13, 14 and 15). 
 
 
Figure 12 - Analysis of the lysate sample of non-transformed E. coli using the analytical method 
based on anion-exchange chromatography. (a) Chromatographic profile of the lysate sample before 
isopropanol precipitation (b) Agarose gel electrophoresis analysis of each peak obtained in the 
chromatogram. Lane M – molecular weight marker; lane 1 – sample injected onto the monolithic column; 






Figure 13 – Analysis of the concentrated lysate sample of non-transformed E. coli using the 
analytical method based on anion-exchange chromatography. (a) Chromatographic profile of the 
lysate sample after isopropanol precipitation (b) Agarose gel electrophoresis analysis of each peak 
obtained in the chromatogram. Lane M – molecular weight marker; lane 1 – sample injected onto the 
monolithic column; lane 2 – 0.38 min-peak. 
 
The analytical chromatograms from Figures 12a and 13a show the peak of non-retained 
species at 0.31 and 0.38 min, respectively. These peaks correspond only to impurities, since 
the E. coli cells were not transformed with the plasmid. Moreover, the lane 2 of each agarose 
gel electrophoresis in Figures 12b and 13b revealed that the peak obtained and recovered in 
each chromatogram (Figures 12a and 13a) corresponds exactly to the sample that was 
injected onto the column (lane 1 in Figures 12b and 13b). 
As the samples of non-transformed E. coli cells do not have pDNA, i.e., the isoform sc is not 
present in this extract, there is no species retained on the column. All this is confirmed since 





Figure 14 - Analysis of lysate sample of transformed E. coli using the analytical method based on 
anion-exchange chromatography. (a) Chromatographic profile of a lysate sample before isopropanol 
precipitation (b) Agarose gel electrophoresis analysis of each peak obtained in the chromatogram. Lane 
M – molecular weight marker; lane 1 – sample injected onto the monolithic column; lane 2 – first peak; 






Figure 15 - Analysis of concentrated lysate sample of transformed E. coli using the analytical 
method based on anion-exchange chromatography. (a) Chromatographic profile of a lysate sample 
after isopropanol precipitation (b) Agarose gel electrophoresis analysis of each peak obtained in the 
chromatogram. Lane M – molecular weight marker; lane 1 – sample injected onto the monolithic column; 
lane 2 – first peak; lane 3 – second peak. 
 
The analytical chromatograms from Figures 14a and 15a show the peak of non-retained 
species at 0.31 and 0.39 min, respectively. As revealed by injection of first recovered fraction 
of each experiment in agarose gel electrophoresis, these peaks correspond to impurities. 
Since, in this case, E. coli cells were transformed with the plasmid, it is justified the 
appearance of the second peak in the chromatograms, corresponding to the sc isoform 
elution, which was retained on the column as revealed by agarose gel electrophoresis (Figures 
14b and 15b).  
Thus, the monolithic column and the method described were tested for different process 
samples recovered at different stages of purification process and the elution pattern used was 







Subsection VI - Clarified lysate enriched with pDNA 
Supercoiled pDNA-containing samples collected in the clarification process after isopropanol 
precipitation (with the chromatographic profile presented in Figure 13a) were further 
enriched with pDNA (oc+sc) and analyzed by the analytical method (Figure 16). Again, the 
chromatogram shows the impurities eluting in the flowthrough, followed by the sc plasmid 
elution, when increasing the ionic strength of the mobile phase. 
 
 
Figure 16 - Analysis of sc pDNA using the analytical method based on anion-exchange 
chromatography. (a) Chromatographic profile of a clarified lysate enriched with pDNA (oc + sc) (b) 
Agarose gel electrophoresis analysis of each peak obtained in the chromatogram. Lane M – molecular 
weight marker; lane 1 – sample injected onto the monolithic column; lane 2 –first peak; lane 3 – second 
peak. 
 
Briefly, a clarified lysate diluted in 700 mM NaCl in 10 mM Tris–HCl pH 8.0 was injected into 
the monolithic column equilibrated with a mobile phase with 760 mM NaCl. In the presence of 
760 mM of NaCl, the impurities were eluted from the column without being retained, whereas 
the sc plasmid showed a higher retention due to its higher charge density, since it presents a 
more compact form which allows a better fit and interaction with ligands within the 
stationary phase pore curvatures. After 2-min elution with the mobile phase used for 
equilibration, the eluent was changed to 1 M NaCl in 10 mM Tris–HCl pH 8.0. With the increase 
of the ionic strength only one resolved peak was eluted (Figure 16a). This peak corresponds to 
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sc pDNA isoform as proven in agarose electrophoresis (Figure 16b). This profile reflects the 
characteristic features of sc pDNA mentioned above. 
The first peak in the chromatogram of Figure 16 was attributed to the impurities present in 
the lysate sample. In fact, control studies carried out at 760 mM NaCl using a clarified lysate 
solution without pDNA (Figures 12 and 13) proved that all impurities eluted with lower 
retention times (≤0.38 min) when compared with the sc pDNA isoform (about 2.7 min). The 
less charged molecules, such as impurities and other conformations of pDNA, are not retained 
in the column and elute immediately. On the other hand, the sc pDNA is retained in the 
column and elute at about 2.7 min due to the increase of the ionic strength of the mobile 
phase. This means that when using this NaCl gradient the sc plasmid peak is not overlapping 
with E. coli impurities. 
Thus, it is possible to conclude that this monolithic column also showed specificity for the sc 
pDNA isoform, applying an E. coli lysate sample. In this way, it may be possible to quantify sc 
pDNA and to assess its purity in different bioprocess steps. 
 
Subsection VII - Validation of the analytical method for impure plasmid 
solutions - Process monitoring 
In order to validate the method developed for impure solutions, a clarified lysate solution 
obtained from a cell culture without plasmid supplemented with known amounts of a pure sc 
plasmid standard (5, 75 and 150 µg/mL sc pDNA) was analyzed in the column (Figure 17). Two 





Figure 17 – Analysis of sc pDNA using the analytical method based on anion-exchange 
chromatography. (a) Chromatographic profiles of a clarified lysate enriched with sc pDNA in different 
concentrations (0, 5, 75, 150 µg/mL) (b) Agarose gel electrophoresis analysis of each peak obtained in 
the chromatograms. Lane M – molecular weight marker; lanes A, B, C and D – sample injected onto the 
monolithic column with a sc pDNA concentration of 0, 5, 75, 150 µg/mL, respectively; lane (A,B,C or D) 






Table 6 - Assessment of sc pDNA in lysate sample enriched with sc pDNA in different concentrations 





concentration ± SD 
(µg/mL) 
CV (%) Mean relative error 
(%) 
5 5.21 ± 0.58 11.13 4.27 
75 80.29 ± 0.69 0.86 7.06 
150 154.50 ± 0.86 0.55 3.00 
 
 
The sc plasmid concentration in all the samples analyzed was determined using the suitable 
standard calibration curve (Figure 6). The standard deviation was found to be lower than 0.86 
µg/mL for all the samples, confirming the reproducibility of the method. The determination 
of the lower sc pDNA concentration (5 µg/mL) shows the highest coefficient of variation 
(about 11 %) and the mean relative errors were lower than 7%. Overall, these results confirm 
the validity of the monolithic method based on AEX chromatography for the quantification of 
sc pDNA in impure solutions. The analytical chromatograms also bear information about the 
purity degree of the samples, which can be estimated as the percentage of the plasmid peak 
area in the chromatogram. 
One of the main advantages emerging from these results is the fact, that a successful 
separation of sc pDNA from cell RNA without any addition of exogenous RNase is feasible. In 
general, if the plasmids are used in the manufacture of pharmaceuticals it is desirable to 
avoid the addition of materials derived from animal, especially bovine sources due to 
concerns regarding bovine spongiform encephalopathies [85]. 
In addition, the applicability of the analytical method was tested for the quantification of 
plasmids prepared with different techniques, i.e., the plasmid samples were purified by AEX 
chromatography, using a commercial kit and by a modification of alkaline method. The 
analytical chromatographic profiles obtained in these assays were similar, because the same 
elution time for the oc and sc pDNA isoforms was achieved. Thus, it was concluded that the 
technique used to purify the plasmid samples, at preparative level, does not influence the 
analytical result. 
Finally, a regeneration of monoliths was also tested and the results showed the possibility of 






Chapter IV - Conclusions  
 
The development of new and optimized methods to quantify pDNA and to assess its purity is 
extremely important regarding the evolving technology to produce plasmids and the increased 
number of clinical trials using plasmids as a biopharmaceutical product. The first analytical 
methods purposed, were not efficient on pDNA isoforms differentiation; however, because of 
the improved relevance attributed to the sc pDNA isoform, new requirements were described, 
and the new methods must be able to isolate and specifically determine plasmid isoforms. 
In this work, an analytical method based on AEX chromatography to quantify and monitor the 
sc pDNA quality was implemented and validated. The experiments performed in a monolithic 
column showed that the technique is specific in sc pDNA assessment. Indeed, the validation of 
the method was performed according to the guidelines, and it was proved that the method is 
linear in a suitable concentration range (2–20 and 20-200 µg/mL). Appropriate lower limits of 
detection and quantification were also obtained. In addition, the precision and accuracy were 
also achieved for this concentration range. Regarding the reproducibility and repeatability, it 
has been concluded that the method is precise and accurate. 
Moreover, a relevant feature of the method is the ability to handle heavily contaminated 
samples without the need for any sample pre-treatment such as digestion of high-molecular-
mass RNA with RNase. Therefore, it was demonstrated that this monolithic column can be 
successfully used for the control of purity and for the quantification of sc pDNA isoform in 
impure process solutions. Replicate analysis of impure samples containing plasmid DNA 
showed that the method is suitable for this purpose. Overall the analytical experiments 
showed that the method is robust. Additionally, a consecutive usage of the same CIM® DEAE 
monolithic column was possible due to a successful regeneration procedure. Moreover, the 
method developed in this work enabled an easy and fast analytical in-process control of the 
sc pDNA purity, completing the run in 4 min, which is an advantage for application in the 








Chapter V - Future Trends 
 
From the conclusions drawn from this thesis also arise some future perspectives to achieve an 
efficient quality control of a biotechnological process. 
The applicability of the analytical method can also be tested for quantification of plasmids 
clarified and purified with other techniques. Thus, as the precipitation with ammonium 
sulphate is generally used as a clarification procedure, some samples prepared with this 
methodology could be assessed. Moreover, plasmid samples purified by hydrophobic 
interaction chromatography and affinity chromatography, at preparative level, could be 
analyzed to conclude if the technique used to purify the plasmid samples influences the 
analytical result. In addition, it could be also interesting to include some analysis of plasmids 
with different sizes and nucleotides composition, in order to understand the influence of 
these parameters on the interaction with the analytical AEX matrix. Large and small plasmids 
should be considered for this study. Furthermore, monitorization of sc pDNA quality could be 
performed for plasmids produced from other hosts. 
On the other hand, some studies could also be developed in order to compare this analytical 
methodology with other techniques to conclude about their applicability in the monitorization 
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